Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multi-center, Randomized, Double-blind, Placebo-controlled Study, to Evaluate the Safety and Efficacy of SB-01 for Injection for the Treatment of Lumbar Degenerative Disc Disease

Next Previous
Trial Profile

A Phase 3, Multi-center, Randomized, Double-blind, Placebo-controlled Study, to Evaluate the Safety and Efficacy of SB-01 for Injection for the Treatment of Lumbar Degenerative Disc Disease

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SB 01-Spine Biopharma (Primary)
  • Indications Back pain; Intervertebral disc degeneration
  • Focus Registrational; Therapeutic Use
  • Acronyms MODEL
  • Sponsors Spine Biopharma

Most Recent Events

  • 27 Sep 2024 Planned End Date changed from 1 Jun 2025 to 27 Aug 2025.
  • 27 Sep 2024 Planned primary completion date changed from 1 Dec 2024 to 27 Feb 2025.
  • 24 Sep 2024 According to Spine BioPharma, Inc media release, the company announced the completion of enrollment of this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top